| |
Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study
|
| |
| |
Download the PDF
April 2024
In conclusion, the exposures to LA cabotegravir and rilpivirine were predicted to be increased in older PWH, but to an extent that does not warrant a dose adjustment in the absence of major comorbid conditions. This finding is reassuring, as it suggests that older PWH could have a lower risk of presenting suboptimal concentrations during the dosing interval. Moreover, the exposures to LA cabotegravir and rilpivirine at steady state were shown to be higher in young or older female compared with young or older male individuals, but to an extent that does not require dose adjustment. Our simulation results should be interpreted with caution in frail individuals, as further clinical studies are needed to investigate the impact of aging and frailty on LA drug exposures and efficacy.
|
|
| |
| |
|
|
|
